SI. No.	State/Union Territories	Allocation for 1994-95	Allocation for 1995-96
2.	Daman & Diu	1.67	3.20
3.	Lakashdweep	1.98	2.80
4.	Pondicherry	1.98	3.20
5.	D. & N. Haveli	1.98	3.20
	TOTAL	2036.80	7495.45

Statcment-II

Amount allocated and achievements under DWCRA in Punjab

	1992-93	1993-94	1994-95 (upt	1995-96 0 Oct., 95)
Amount allocated (Rs. in Lakhs)	31.92	72.20.	80.56	165.75
Amount utilised (Rs, in lakhs)	49.00.	39.60	68.34	37.53
No of groups formed	336	545	502	242
No. of beneficiaries	6526	6050	6151	2954

Anti-Cancer Drug

2540. SHRI KRISHAN LAL SHARMA; Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that a leading indigenous pharmaceutical company has developed a new anti-cancer drug known as Intaxel;

(b) whether it is also a fact that the treatment with the said drug is 50% economical as. compared to the imported drug;

(c) whether the pharmaceutical company has filed for patient rights in the U.S.A. for process leading to the marketing of the drug; and

(d) if so, the results thereof?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI A.R. ANTULAY): (a) Yes Sir. Intaxel which is a brand of Pacillitaxel is avaiable for the treatment of metastatic ovarian cancer resistent to first line therapy.

(b) The indigenously manufactured drug is less than half the cost of the imported drug.

(c) No, Sir. Intaxel is a formation of natural Paclitaxel which cannot be patented.

(d) Does not arise.

Financial Assistance from NRF to Gujarat

2541. SHRIMATI NAt*D»EN JETHABHAI PATEL: Will the Minister of INDUSTRY be pleased to state:

(a) whether Gujarat Government has